BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6.1% higher at $111.6. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 19% gain over the past four weeks.
The growing investor optimism related to the company’s novel investigative therapies, which are being developed for treating cancer and other serious diseases, might have driven the recent share price rally.
This company is expected to post quarterly loss of $2.52 per share in its upcoming report, which represents a year-over-year change of -38.5%. Revenues are expected to be $214.62 million, up 11.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For BioNTech, the consensus EPS estimate for the quarter has been revised 27.4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BNTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
BioNTech is part of the Zacks Medical - Biomedical and Genetics industry. Genmab A/S Sponsored ADR (GMAB), another stock in the same industry, closed the last trading session 3% lower at $27.06. GMAB has returned 8.7% in the past month.
Genmab's consensus EPS estimate for the upcoming report has changed +2.2% over the past month to $0.15. Compared to the company's year-ago EPS, this represents a change of -51.6%. Genmab currently boasts a Zacks Rank of #3 (Hold).
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
Genmab A/S Sponsored ADR (GMAB): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).